中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (4): 279-288.doi: 10.35541/cjd.20201078
中华医学会皮肤性病学分会玫瑰痤疮研究中心 中国医师协会皮肤科医师分会玫瑰痤疮专业委员会
收稿日期:2020-11-09
修回日期:2020-12-23
发布日期:2021-03-31
通讯作者:
李吉；谢红付
E-mail:lydia.1208@hotmail.com; xiehongfu@csu.edu.cn
Rosacea Research Center, Chinese Society of Dermatology; Rosacea Professional Committee, Chinese Dermatologist Association
Received:2020-11-09
Revised:2020-12-23
Published:2021-03-31
Contact:
Li Ji; Xie Hongfu
E-mail:lydia.1208@hotmail.com; xiehongfu@csu.edu.cn
摘要： 【摘要】 玫瑰痤疮是一种好发于面中部的慢性炎症性皮肤病，主要表现为面中部反复潮红、红斑。近年来，对本病的诊治有了新的认识，为此，组织部分专家在《中国玫瑰痤疮诊疗专家共识（2016）》的基础上制定本指南，新版指南提出了分部位诊断标准，希望能进一步规范我国玫瑰痤疮的诊断与治疗。
中华医学会皮肤性病学分会玫瑰痤疮研究中心 中国医师协会皮肤科医师分会玫瑰痤疮专业委员会. 中国玫瑰痤疮诊疗指南（2021版）[J]. 中华皮肤科杂志, 2021,54(4):279-288. doi:10.35541/cjd.20201078
Rosacea Research Center, Chinese Society of Dermatology, Rosacea Professional Committee, Chinese Dermatologist Association. Guidelines for the diagnosis and treatment of rosacea in China （2021 edition）[J]. Chinese Journal of Dermatology, 2021, 54(4): 279-288.doi:10.35541/cjd.20201078
| ［1］ | 张建中，高兴华. 皮肤性病学. 北京: 人民卫生出版社, 2015:296. |
| ［2］ | Gether L, Overgaard LK, Egeberg A, et al. Incidence and prevalence of rosacea: a systematic review and meta⁃analysis［J］. Br J Dermatol, 2018,179（2）:282⁃289. doi: 10.1111/bjd. 16481. |
| ［3］ | Li J, Wang B, Deng Y, et al. Epidemiological features of rosacea in Changsha, China: a population⁃based, cross⁃sectional study［J］. J Dermatol, 2020,47（5）:497⁃502. doi: 10.1111/1346⁃8138. 15301. |
| ［4］ | Zuo Z, Wang B, Shen M, et al. Skincare habits and rosacea in 3,439 Chinese adolescents: a university⁃based cross⁃sectional study［J］. Acta Derm Venereol, 2020,100（6）:adv00081. doi: 10.2340/00015555⁃3442. |
| ［5］ | Spoendlin J, Voegel JJ, Jick SS, et al. A study on the epidemiology of rosacea in the U.K［J］. Br J Dermatol, 2012,167（3）:598⁃605. doi: 10.1111/j.1365⁃2133.2012.11037.x. |
| ［6］ | 李吉, 何琳, 谢红付, 等. 玫瑰痤疮分型再认识［J］. 实用医院临床杂志, 2015,（2）:1⁃2. doi: 10.3969/j.issn.1672⁃6170.2015. 02.001. |
| ［7］ | Aldrich N, Gerstenblith M, Fu P, et al. Genetic vs environmental factors that correlate with rosacea: a cohort⁃based survey of twins［J］. JAMA Dermatol, 2015,151（11）:1213⁃1219. doi: 10.1001/jamadermatol.2015.2230. |
| ［8］ | Chang A, Raber I, Xu J, et al. Assessment of the genetic basis of rosacea by genome⁃wide association study［J］. J Invest Dermatol, 2015,135（6）:1548⁃1555. doi: 10.1038/jid.2015.53. |
| ［9］ | Schwab VD, Sulk M, Seeliger S, et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea［J］. J Investig Dermatol Symp Proc, 2011,15（1）:53⁃62. doi: 10.1038/jidsymp.2011.6. |
| ［10］ | Buddenkotte J, Steinhoff M. Recent advances in understanding and managing rosacea［J］. F1000Res, 2018,7. doi: 10.12688/f1000research.16537.1. |
| ［11］ | Haber R, El Gemayel M. Comorbidities in rosacea: a systematic review and update［J］. J Am Acad Dermatol, 2018,78（4）:786⁃792.e8. doi: 10.1016/j.jaad.2017.09.016. |
| ［12］ | 杨赛, 谢红付, 邓宇瑄, 等. A型性格与玫瑰痤疮的相关性研究［J］. 临床皮肤科杂志, 2014,43（12）:707⁃709. doi: 10.16761/j.cnki.1000⁃4963.2014.12.016. |
| ［13］ | Liu T, Deng Z, Xie H, et al. ADAMDEC1 promotes skin inflammation in rosacea via modulating the polarization of M1 macrophages［J］. Biochem Biophys Res Commun, 2020,521（1）:64⁃71. doi: 10.1016/j.bbrc.2019.10.073. |
| ［14］ | Yamasaki K, Kanada K, Macleod DT, et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes［J］. J Invest Dermatol, 2011,131（3）:688⁃697. doi: 10.1038/jid.2010.351. |
| ［15］ | Antal AS, Dombrowski Y, Koglin S, et al. Impact of vitamin D3 on cutaneous immunity and antimicrobial peptide expression［J］. Dermatoendocrinol, 2011,3（1）:18⁃22. doi: 10.4161/derm.3. 1.14616. |
| ［16］ | Park K, Elias PM, Oda Y, et al. Regulation of cathelicidin antimicrobial peptide expression by an endoplasmic reticulum （ER） stress signaling, vitamin D receptor⁃independent pathway［J］. J Biol Chem, 2011,286（39）:34121⁃34130. doi: 10.1074/jbc.M111.250431. |
| ［17］ | Meyer⁃Hoffert U, Schröder JM. Epidermal proteases in the pathogenesis of rosacea［J］. J Investig Dermatol Symp Proc, 2011,15（1）:16⁃23. doi: 10.1038/jidsymp.2011.2. |
| ［18］ | Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea［J］. Nat Med, 2007,13（8）:975⁃980. doi: 10.1038/nm 1616. |
| ［19］ | Kim J, Ochoa MT, Krutzik SR, et al. Activation of toll⁃like receptor 2 in acne triggers inflammatory cytokine responses［J］. J Immunol, 2002,169（3）:1535⁃1541. doi: 10.4049/jimmunol.169. 3.1535. |
| ［20］ | 吴艳, 牛悦青, 陈璨, 等. 皮肤屏障与玫瑰痤疮相关性的研究进展［J］. 皮肤病与性病, 2011,33（2）:77⁃78. doi: 10.3969/j.issn.1002⁃1310.2011.02.008. |
| ［21］ | 吴琰瑜, 王学民. 乳酸刺痛反应对玫瑰痤疮患者局部皮肤敏感性的评价［J］. 临床皮肤科杂志, 2005,34（7）:439⁃440. doi: 10.3969/j.issn.1000⁃4963.2005.07.010. |
| ［22］ | Deng Z, Chen M, Xie H, et al. Claudin reduction may relate to an impaired skin barrier in rosacea［J］. J Dermatol, 2019,46（4）:314⁃321. doi: 10.1111/1346⁃8138.14792. |
| ［23］ | 袁超, 王学民. 微生物在玫瑰痤疮发病机制中的作用［J］. 中国皮肤性病学杂志, 2015,29（5）:521⁃523. doi: 10.13735/j.cjdv. 1001⁃7089.201402101.. |
| ［24］ | Lacey N, Delaney S, Kavanagh K, et al. Mite⁃related bacterial antigens stimulate inflammatory cells in rosacea［J］. Br J Dermatol, 2007,157（3）:474⁃481. doi: 10.1111/j.1365⁃2133.2007. 08028.x. |
| ［25］ | Holmes AD. Potential role of microorganisms in the pathogenesis of rosacea［J］. J Am Acad Dermatol, 2013,69（6）:1025⁃1032. doi: 10.1016/j.jaad.2013.08.006. |
| ［26］ | Bonamigo RR, Leite CS, Wagner M, et al. Rosacea and Helicobacter pylori: interference of systemic antibiotic in the study of possible association［J］. J Eur Acad Dermatol Venereol, 2000,14（5）:424⁃425. doi: 10.1046/j.1468⁃3083.2000.00090⁃3.x. |
| ［27］ | Chen X, Takai T, Xie Y, et al. Human antimicrobial peptide LL⁃37 modulates proinflammatory responses induced by cytokine milieus and double⁃stranded RNA in human keratinocytes［J］. Biochem Biophys Res Commun, 2013,433（4）:532⁃537. doi: 10. 1016/j.bbrc.2013.03.024. |
| ［28］ | Holmes AD, Steinhoff M. Integrative concepts of rosacea pathophysiology, clinical presentation and new therapeutics［J］. Exp Dermatol, 2017,26（8）:659⁃667. doi: 10.1111/exd.13143. |
| ［29］ | Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea［J］. J Am Acad Dermatol, 2002,46（4）:584⁃587. doi: 10.1067/mjd.2002. 120625. |
| ［30］ | Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee［J］. J Am Acad Dermatol, 2018,78（1）:148⁃155. doi: 10.1016/j.jaad.2017.08.037. |
| ［31］ | 汪犇, 赵志祥, 简丹, 等. 中国玫瑰痤疮临床特征分析和诊断标准再探讨［J］. 中华皮肤科杂志, 2020,53（9）:675⁃679. doi: 10.35541/cjd.20200376. |
| ［32］ | van Zuuren EJ, van der Linden M, Arents B. Rosacea treatment guideline for the Netherlands［J］. Br J Dermatol, 2020,182（6）:1504⁃1506. doi: 10.1111/bjd.18882. |
| ［33］ | Sgouros D, Apalla Z, Ioannides D, et al. Dermoscopy of common inflammatory disorders［J］. Dermatol Clin, 2018,36（4）:359⁃368. doi: 10.1016/j.det.2018.05.003. |
| ［34］ | Holmes AD, Steinhoff M. Integrative concepts of rosacea pathophysiology, clinical presentation and new therapeutics［J］. Exp Dermatol, 2017,26（8）:659⁃667. doi: 10.1111/exd.13143. |
| ［35］ | Nicholson K, Abramova L, Chren MM, et al. A pilot quality⁃of⁃life instrument for acne rosacea［J］. J Am Acad Dermatol, 2007,57（2）:213⁃221. doi: 10.1016/j.jaad.2007.01.048. |
| ［36］ | Park JY, Ahn MK, Cho EB, et al. Dual⁃frequency ultrasound as a new treatment modality for refractory rosacea: a retrospective study［J］. Dermatol Surg, 2018,44（9）:1209⁃1215. doi: 10.1097/DSS.0000000000001552. |
| ［37］ | König K, Speicher M, Bückle R, et al. Clinical optical coherence tomography combined with multiphoton tomography of patients with skin diseases［J］. J Biophotonics, 2009,2（6⁃7）:389⁃397. doi: 10.1002/jbio.200910013. |
| ［38］ | Wilkin JK, Josephs JA. Infrared photographic studies of rosacea［J］. Arch Dermatol, 1980,116（6）:676⁃678. doi: 10.1001/archderm.1980.01640300064019. |
| ［39］ | Kawata AK, Revicki DA, Thakkar R, et al. Flushing ASsessment Tool （FAST）: psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy［J］. Clin Drug Investig, 2009,29（4）:215⁃229. doi: 10. 2165/00044011⁃200929040⁃00001. |
| ［40］ | Norquist JM, Watson DJ, Yu Q, et al. Validation of a questionnaire to assess niacin⁃induced cutaneous flushing［J］. Curr Med Res Opin, 2007,23（7）:1549⁃1560. doi: 10.1185/0300 79907x199637. |
| ［41］ | Tan J, Liu H, Leyden JJ, et al. Reliability of clinician erythema assessment grading scale［J］. J Am Acad Dermatol, 2014,71（4）:760⁃763. doi: 10.1016/j.jaad.2014.05.044. |
| ［42］ | Tan J, Leoni M. Erythema of rosacea: validation of patient′s self⁃assessment grading scale［J］. J Drugs Dermatol, 2015,14（8）:841⁃844. |
| ［43］ | Kim J, Ahn JW, Ha S, et al. Clinical assessment of rosacea severity: oriental score vs. quantitative assessment method with imaging and biomedical tools［J］. Skin Res Technol, 2017,23（2）:186⁃193. doi: 10.1111/srt.12318. |
| ［44］ | Nilges P, Essau C. Depression, anxiety and stress scales: DASS⁃⁃A screening procedure not only for pain patients［J］. Schmerz, 2015,29（6）:649⁃657. doi: 10.1007/s00482⁃015⁃0019⁃z. |
| ［45］ | Meyer TJ, Miller ML, Metzger RL, et al. Development and validation of the Penn State Worry Questionnaire［J］. Behav Res Ther, 1990,28（6）:487⁃495. doi: 10.1016/0005⁃7967（90）90135⁃6. |
| ［46］ | Deng Y, Peng Q, Yang S, et al. The rosacea⁃specific quality⁃of⁃life instrument （RosQol）: revision and validation among Chinese patients［J/OL］. PLoS One, 2018,13（2）:e0192487. doi: 10.1371/journal.pone.0192487. |
| ［47］ | Schaller M, Almeida L, Bewley A, et al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel［J］. Br J Dermatol, 2020,182（5）:1269⁃1276. doi: 10.1111/bjd.18420. |
| ［48］ | Anzengruber F, Czernielewski J, Conrad C, et al. Swiss S1 guideline for the treatment of rosacea［J］. J Eur Acad Dermatol Venereol, 2017,31（11）:1775⁃1791. doi: 10.1111/jdv.14349. |
| ［49］ | 中国医师协会皮肤科医师分会皮肤美容亚专业委员会. 中国玫瑰痤疮诊疗专家共识（2016）［J］. 中华皮肤科杂志, 2017,50（3）:156⁃161. doi: 10.3760/cma.j.issn.0412⁃4030.2017.03.002. |
| ［50］ | Li G, Wang B, Zhao Z, et al. Excessive cleansing: an underestimating risk factor of rosacea in Chinese population［J］. Arch Dermatol Res, 2020. doi: 10.1007/s00403⁃020⁃02095⁃w. |
| ［51］ | Xie H, Xiao X, Li J. Topical steroids in Chinese cosmetics［J］. JAMA Dermatol, 2017,153（9）:855⁃856. doi: 10.1001/jamadermatol.2017.1615. |
| ［52］ | Huang YX, Li J, Zhao ZX, et al. Effects of skin care habits on the development of rosacea: a multi⁃center retrospective case⁃control survey in Chinese population［J/OL］. PLoS One, 2020,15（4）:e0231078. doi: 10.1371/journal.pone.0231078. |
| ［53］ | Koca R, Altinyazar HC, Ankarali H, et al. A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: a randomized open⁃label clinical trial［J］. Clin Exp Dermatol, 2010,35（3）:251⁃256. doi: 10.1111/j.1365⁃2230.2009.03427.x. |
| ［54］ | Breneman D, Savin R, VandePol C, et al. Double⁃blind, randomized, vehicle⁃controlled clinical trial of once⁃daily benzoyl peroxide/clindamycin topical gel in the treatment of patients with moderate to severe rosacea［J］. Int J Dermatol, 2004,43（5）:381⁃387. doi: 10.1111/j.1365⁃4632.2004.02283.x. |
| ［55］ | Sahni DR, Feldman SR, Taylor SL. Ivermectin 1% （CD5024） for the treatment of rosacea［J］. Expert Opin Pharmacother, 2018,19（5）:511⁃516. doi: 10.1080/14656566.2018.1447562. |
| ［56］ | Thiboutot D, Thieroff⁃Ekerdt R, Graupe K. Efficacy and safety of azelaic acid （15%） gel as a new treatment for papulopustular rosacea: results from two vehicle⁃controlled, randomized phase III studies［J］. J Am Acad Dermatol, 2003,48（6）:836⁃845. doi: 10.1067/mjd.2003.308. |
| ［57］ | Oztürkcan S, Ermertcan AT, Sahin MT, et al. Efficiency of benzoyl peroxide⁃erythromycin gel in comparison with metronidazole gel in the treatment of acne rosacea［J］. J Dermatol, 2004,31（8）:610⁃617. doi: 10.1111/j.1346⁃8138.2004.tb00566.x. |
| ［58］ | Two AM, Wu W, Gallo RL, et al. Rosacea: part II. Topical and systemic therapies in the treatment of rosacea［J］. J Am Acad Dermatol, 2015,72（5）:761⁃770; quiz 771⁃772. doi: 10.1016/j.jaad.2014.08.027. |
| ［59］ | Eichenfield LF, Del Rosso JQ, Tan J, et al. Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1.0% for persistent erythema of rosacea in a phase IV study［J］. Br J Dermatol, 2019,180（5）:1050⁃1057. doi: 10.1111/bjd.17462. |
| ［60］ | Wang L, Li XH, Wen X, et al. Retrospective analysis of 19 papulopustular rosacea cases treated with oral minocycline and supramolecular salicylic acid 30% chemical peels［J］. Exp Ther Med, 2020,20（2）:1048⁃1052. doi: 10.3892/etm.2020.8740. |
| ［61］ | Mantelli F, Di Zazzo A, Sacchetti M, et al. Topical azithromycin as a novel treatment for ocular rosacea［J］. Ocul Immunol Inflamm, 2013,21（5）:371⁃377. doi: 10.3109/09273948.2013. 801991. |
| ［62］ | Arman A, Demirseren DD, Takmaz T. Treatment of ocular rosacea: comparative study of topical cyclosporine and oral doxycycline［J］. Int J Ophthalmol, 2015,8（3）:544⁃549. doi: 10. 3980/j.issn.2222⁃3959.2015.03.19. |
| ［63］ | Wladis EJ, Adam AP. Treatment of ocular rosacea［J］. Surv Ophthalmol, 2018,63（3）:340⁃346. doi: 10.1016/j.survophthal. 2017.07.005. |
| ［64］ | Mori A, Shimazaki J, Shimmura S, et al. Disposable eyelid⁃warming device for the treatment of meibomian gland dysfunction［J］. Jpn J Ophthalmol, 2003,47（6）:578⁃586. doi: 10.1016/s0021⁃5155（03）00142⁃4. |
| ［65］ | Elewski BE, Draelos Z, Dréno B, et al. Rosacea ⁃ global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group［J］. J Eur Acad Dermatol Venereol, 2011,25（2）:188⁃200. doi: 10.1111/j.1468⁃3083.2010.03751.x. |
| ［66］ | van der Linden M, van Ratingen AR, van Rappard DC, et al. DOMINO, doxycycline 40 mg vs. minocycline 100 mg in the treatment of rosacea: a randomized, single⁃blinded, noninferiority trial, comparing efficacy and safety［J］. Br J Dermatol, 2017,176（6）:1465⁃1474. doi: 10.1111/bjd.15155. |
| ［67］ | Dahl MV, Katz HI, Krueger GG, et al. Topical metronidazole maintains remissions of rosacea［J］. Arch Dermatol, 1998,134（6）:679⁃683. doi: 10.1001/archderm.134.6.679. |
| ［68］ | Rallis E, Korfitis C. Isotretinoin for the treatment of granulomatous rosacea: case report and review of the literature［J］. J Cutan Med Surg, 2012,16（6）:438⁃441. doi: 10.1177/1203 47541201600615. |
| ［69］ | Rademaker M. Very low⁃dose isotretinoin in mild to moderate papulopustular rosacea; a retrospective review of 52 patients［J］. Australas J Dermatol, 2018,59（1）:26⁃30. doi: 10.1111/ajd.12522. |
| ［70］ | Wang B, Yuan X, Huang X, et al. Efficacy and safety of hydroxychloroquine for treatment of patients with rosacea: a multicenter, randomized, double⁃blind, double⁃dummy, pilot study［J］. J Am Acad Dermatol, 2021,84（2）:543⁃545. doi: 10. 1016/j.jaad.2020.05.050. |
| ［71］ | 刘英姿, 谢红付, 李吉, 等. 羟氯喹治疗60例轻中度酒渣鼻的有效性及安全性临床观察［J］. 临床皮肤科杂志, 2015,44（4）:254⁃257. |
| ［72］ | Hsu CC, Lee JY. Carvedilol for the treatment of refractory facial flushing and persistent erythema of rosacea［J］. Arch Dermatol, 2011,147（11）:1258⁃1260. doi: 10.1001/archdermatol.2011.204. |
| ［73］ | Waldinger MD, Berendsen HH, Schweitzer DH. Treatment of hot flushes with mirtazapine: four case reports［J］. Maturitas, 2000,36（3）:165⁃168. doi: 10.1016/s0378⁃5122（00）00152⁃3. |
| ［74］ | Orleans RJ, Li L, Kim MJ, et al. FDA approval of paroxetine for menopausal hot flushes［J］. N Engl J Med, 2014,370（19）:1777⁃1779. doi: 10.1056/NEJMp1402080. |
| ［75］ | Fawaz B, Chamseddin BH, Griffin JR. Defining the role of mirtazapine in the treatment of refractory pruritus［J］. J Dermatolog Treat, 2019:1⁃5. doi: 10.1080/09546634.2019.1630702. |
| ［76］ | Taub AF. Treatment of rosacea with intense pulsed light［J］. J Drugs Dermatol, 2003,2（3）:254⁃259. |
| ［77］ | Mark KA, Sparacio RM, Voigt A, et al. Objective and quantitative improvement of rosacea⁃associated erythema after intense pulsed light treatment［J］. Dermatol Surg, 2003,29（6）:600⁃604. doi: 10.1046/j.1524⁃4725.2003.29141.x. |
| ［78］ | Taub AF, Devita EC. Successful treatment of erythemato⁃telangiectatic rosacea with pulsed light and radiofrequency［J］. J Clin Aesthet Dermatol, 2008,1（1）:37⁃40. |
| ［79］ | Bernstein EF, Kligman A. Rosacea treatment using the new⁃generation, high⁃energy, 595 nm, long pulse⁃duration pulsed⁃dye laser［J］. Lasers Surg Med, 2008,40（4）:233⁃239. doi: 10.1002/lsm.20621. |
| ［80］ | Tan SR, Tope WD. Pulsed dye laser treatment of rosacea improves erythema, symptomatology, and quality of life［J］. J Am Acad Dermatol, 2004,51（4）:592⁃599. doi: 10.1016/j.jaad. 2004.04.010. |
| ［81］ | Moreira A, Leite I, Guedes R, et al. Surgical treatment of rhinophyma using carbon dioxide （CO2） laser and pulsed dye laser （PDL）［J］. J Cosmet Laser Ther, 2010,12（2）:73⁃76. doi: 10.3109/14764171003706208. |
| ［82］ | Neuhaus IM, Zane LT, Tope WD. Comparative efficacy of nonpurpuragenic pulsed dye laser and intense pulsed light for erythematotelangiectatic rosacea［J］. Dermatol Surg, 2009,35（6）:920⁃928. doi: 10.1111/j.1524⁃4725.2009.01156.x. |
| ［83］ | Alam M, Dover JS, Arndt KA. Treatment of facial telangiectasia with variable⁃pulse high⁃fluence pulsed⁃dye laser: comparison of efficacy with fluences immediately above and below the purpura threshold［J］. Dermatol Surg, 2003,29（7）:681⁃684; discussion 685. doi: 10.1046/j.1524⁃4725.2003.29181.x. |
| ［84］ | Jasim ZF, Woo WK, Handley JM. Long⁃pulsed （6⁃ms） pulsed dye laser treatment of rosacea⁃associated telangiectasia using subpurpuric clinical threshold［J］. Dermatol Surg, 2004,30（1）:37⁃40. doi: 10.1111/j.1524⁃4725.2004.30001.x. |
| ［85］ | Madan V, Ferguson JE, August PJ. Carbon dioxide laser treatment of rhinophyma: a review of 124 patients［J］. Br J Dermatol, 2009,161（4）:814⁃818. doi: 10.1111/j.1365⁃2133.2009. 09317.x. |
| ［86］ | Serowka KL, Saedi N, Dover JS, et al. Fractionated ablative carbon dioxide laser for the treatment of rhinophyma［J］. Lasers Surg Med, 2014,46（1）:8⁃12. doi: 10.1002/lsm.22184. |
| ［87］ | Lee JH, Kim M, Bae JM, et al. Efficacy of the long⁃pulsed 1064⁃nm neodymium:yttrium⁃aluminum⁃garnet laser （LPND） （rejuvenation mode） in the treatment of papulopustular rosacea （PPR）: a pilot study of clinical outcomes and patient satisfaction in 30 cases［J］. J Am Acad Dermatol, 2015,73（2）:333⁃336. doi: 10.1016/j.jaad.2015.05.030. |
| ［88］ | Kim SJ, Lee Y, Seo YJ, et al. Comparative efficacy of radiofrequency and pulsed dye laser in the treatment of rosacea［J］. Dermatol Surg, 2017,43（2）:204⁃209. doi: 10.1097/DSS.0000000000000968. |
| ［89］ | Fan L, Yin R, Lan T, et al. Photodynamic therapy for rosacea in Chinese patients［J］. Photodiagnosis Photodyn Ther, 2018,24:82⁃87. doi: 10.1016/j.pdpdt.2018.08.005. |
| ［90］ | Zide MF. Surgical removal of rhinophyma［J］. J Oral Maxillofac Surg, 2008,66（10）:2168⁃2177. doi: 10.1016/j.joms.2008.01.036. |
| ［91］ | Tüzün Y, Wolf R, Kutlubay Z, et al. Rosacea and rhinophyma［J］. Clin Dermatol, 2014,32（1）:35⁃46. doi: 10.1016/j.clindermatol.2013.05.024. |
| ［92］ | 李铁男, 刘岩. 中晚期酒渣鼻最佳治疗方案的探讨［J］. 中国美容医学, 1996,（3）:160⁃162. doi: 10.15909/j.cnki.cn61⁃1347/r. 1996.03.023. |
| ［93］ | 王学军, 李铁男, 郭春芳, 等. 15例巨大酒渣鼻临床医疗分析［J］. 中国中西医结合皮肤性病学杂志, 2006,5（3）:171⁃172. doi: 10.3969/j.issn.1672⁃0709.2006.03.027. |
| ［94］ | Metternich FU, Wenzel S, Sagowski C, et al. Surgical treatment of rhinophyma with the ultrasonic scalpel （Ultracision Harmonic Scalpel）［J］. Laryngorhinootologie, 2003,82（2）:132⁃137. doi: 10.1055/s⁃2003⁃37731. |
| ［95］ | Sartim MA, Menaldo DL, Sampaio SV. Immunotherapeutic potential of Crotoxin: anti⁃inflammatory and immunosuppressive properties［J］. J Venom Anim Toxins Incl Trop Dis, 2018,24:39. doi: 10.1186/s40409⁃018⁃0178⁃3. |
| [1] | 张宁, 李舒, 李敬. 免疫检查点抑制剂和靶向药物辅助治疗可切除黑素瘤疗效的网状Meta分析[J]. 中华皮肤科杂志, 2022, 0(4): 20200767-e20200767. |
| [2] | 李妍 李明 徐薇 李邻峰. 【开放获取】丙酸氟替卡松乳膏单独或联合卡泊三醇软膏治疗轻中度斑块状银屑病的随机自身对照研究[J]. 中华皮肤科杂志, 2022, 55(3): 260-263. |
| [3] | 李浩, 王俐 韩宪伟 孙彤 苏芳 孙晓冬 韩莹 杨国玲 刘晓明 王凯波 . 糖尿病患者服用二肽基肽酶Ⅳ抑制剂后发生大疱性类天疱疮32例临床特征分析[J]. 中华皮肤科杂志, 2022, 55(3): 213-218. |
| [4] | 《脓疱型银屑病诊疗中国专家共识（版）》编写委员会专家组. 脓疱型银屑病诊疗中国专家共识（2022版）[J]. 中华皮肤科杂志, 2022, 55(3): 187-195. |
| [5] | 王娟娟 陈容 季江 苏文星 魏钰倩 赵莹 尹兴平 苏玉华 施辛. 以精神行为异常为首发症状的67例神经梅毒患者回顾性分析[J]. 中华皮肤科杂志, 2022, 55(3): 231-234. |
| [6] | 吕玲 吕小岩. 皮肌炎伴发恶性肿瘤的研究进展[J]. 中华皮肤科杂志, 2022, 55(3): 276-279. |
| [7] | 李锁 向睿宇 李志量 荆可 王媛 张寒梅 冯素英. 盐裂皮肤间接免疫荧光技术在大疱性类天疱疮诊断中的价值评估[J]. 中华皮肤科杂志, 2022, 55(3): 235-237. |
| [8] | 欧敏, 颜韵灵, 郑宝庆, 王晓华. 银屑病与肥胖相关性的研究进展[J]. 中华皮肤科杂志, 2022, 55(2): 181-184. |
| [9] | 包诗杰, 程杨, 晏莹, 范昉, 高婷婷, 冯小兰, 郑亮, 雷卫, 黄琴斯, 张伟明, 周小勇. 人免疫球蛋白和重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗中毒性表皮坏死松解症的对比研究[J]. 中华皮肤科杂志, 2022, 55(2): 153-156. |
| [10] | 温广东 冒丹丹 张原媛 窦沅青 赵培 吴晨雨 张建中. 【开放获取】度普利尤单抗治疗泛发性苔藓状淀粉样变1例国内首报[J]. 中华皮肤科杂志, 2022, 0(2): 20210694-e20210694. |
| [11] | 焦晓燕, 尹光文, 阴亚坤, 李冬芹. 妊娠期、围生期带状疱疹25例临床分析[J]. 中华皮肤科杂志, 2022, 0(2): 20210384-e20210384. |
| [12] | 王佳绮, 王平, 李刘雨, 樊奇敏, 朱蒙燕, 王燕清, 周鸿宇, 沈宏, 许爱娥. 皮肤色素减退性淋巴增殖性疾病41例临床病理分析[J]. 中华皮肤科杂志, 2022, 55(2): 110-115. |
| [13] | 李赛, 薛华忠, 张树文, 蒋娟, 齐淑贞, 赵园园, 张津萍, 沙仲, 乐文静, 王碧伟, 赵诗轩, 朱小凤, 苏晓红. 多西环素-莫西沙星序贯疗法治疗生殖支原体尿道炎/宫颈炎的临床观察[J]. 中华皮肤科杂志, 2022, 0(2): 20210631-e20210631. |
| [14] | 王小燕, 张嘉文, 刘韵祎, 刘乙萱, 姜沛彧, 李敏, 陶梦, 许阳. 玫瑰痤疮的皮肤影像学和无创检测技术相关进展[J]. 中华皮肤科杂志, 2022, 0(1): 20200939-e20200939. |
| [15] | 程必红, 窦侠. 慢性痒疹的诊断及分型新进展[J]. 中华皮肤科杂志, 2022, 0(1): 20210130-e20210130. |
|
